The FDA and EMA expressed the need for trial sponsors to coordinate their submissions of initial pediatric study plans and pediatric investigation plans for new oncology drugs.
Most patients with CML are being prescribed costly second-generation TKIs, even though generic imatinib has been available since 2016.
Patients with severe COVID-19 may benefit from a fixed-dose or shock-dependent dosing of hydrocortisone, but early study termination hindered definitive conclusions.
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who had an L265P MYD88 mutation were uncommon and had distinct features.
Risk-adapted dosing of bendamustine and rituximab may be beneficial and tolerable for elderly patients with CLL, a retrospective study found.
Even with an “exponential growth” of URM students, “faculty diversity would remain static well into the next 50 years.”
The FDA issued a clinical hold for a trial evaluating a universal CAR T-cell product in patients with relapsed or refractory multiple myeloma after 1 patient died.
The Consistent Testing Terminology Working Group selected plain language terminology that can be used when communicating with cancer patients about genetic testing.
The NCCN recently released 2 sets of Guidelines for Patients that explain the side effects of different types of immunotherapies, such as CAR T-cell therapies.
Patients with chronic lymphocytic leukemia who are treated with ibrutinib may have a higher incidence of atrial fibrillation than previously thought.
